Quantitative assessment of fibrinogen cross-linking by εaminocaproic acid in patients with end-stage liver disease

Liver Transplantation

Volumn 10, Issue 1, 2004, Pages 123-128

  Quach, Thien ^a   Tippens, Melissa ^a   Szlam, Fania ^b   Van Dyke, Rebecca ^a   Levy, Jerrold H ^b   Csete, Marie ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; FIBRINOGEN; FLUORESCEIN ISOTHIOCYANATE; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CHEMICAL ENGINEERING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SPECTROFLUOROMETRY;

6-AMINOCAPROIC ACID; ADULT; ANTIFIBRINOLYTIC AGENTS; CROSS-LINKING REAGENTS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; FLUOROMETRY; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 3042730958     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20011     Document Type: Article

References (24)

1. De Maat MP, Nieuwenhuizen W, Knot EA, van Buuren HR, Swart GR. Measuring plasma fibrinogen levels in patients with liver cirrhosis. The occurrence of proteolytic fibrin(ogen) degradation products and their influence on several fibrinogen assays. Thromb Res 1995;78:353-362.
2. Goodpasture EW. Fibrinolysis in chronic hepatic insufficiency. Bull Johns Hopkins Hosp 1914;25:330-336.
3. Hu HQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001;96:1581-1586.
4. Porte RJ, Bontempo FA, Knot EA, Lewis JH, Kang YG, Starzl TE. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989;47:978-984.
5. Kang Y, Lewis JH, Navalgund A, Russell MV, Bontempo FA, Niren LS, Starzl TE. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987; 66:766-773.
6. Dalmau A. Sabate A, Acosta F, Garcia-Huete L, Koo M, Reche M, Rafecas A, Figueras J, Jaurrieta E. Comparative study of antifibrinolytic drugs in orthotopic liver transplantation. Transplant Proc 1999;31:2361-2362.
7. McNicol GP, Fletcher AP, Alkjaersig N, Sherry S. The absorption, distribution, and excretion of ε-aminocaproic acid following oral or intravenous administration to man. J Lab Clin Med 1962; 59:15-24.
8. Genton E., Fletcher AP, Alkjaersig N, Sherry S. Assay of plasma thrombolytic activity with fluorescein-labeled clots. J Lab Clin Med 1964;64:313-320.
9. Wu J-H, Diamond SL. A fluorescence quench and dequench assay of fibrinogen polymerization, fibrinogenolysis, or fibrinolysis. Anal Biochem 1995;224:83-91.
10. Wu J-H, Diamond SL. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions. Thromb Haemost 1995;74:711-717.
11. Ririe DG, James RL, O'Brien JJ, Lin YA, Bennett J, Barclay D, Hines MH, Butterworth JF. The pharmacokinetics of ε-Aminocaprioic acid in children undergoing surgical repair of congenital heart defects. Anesth Analg 2002;94:44-49.
12. Lam S. High performance liquid chromatographic assay of Amicar, ε-Aminocaproic acid, in plasma and urine after pre-column derivatization with o-phtalaldehyde for fluorescence detection. Biomed Chromatogr 1990;4:175-177.
13. Bennett-Guerrero E, Sorohan JG, Canada AT, Ayuso L, Newman MF, Reves JG, Mythen MG. Epsilon-aminocaproic acid plasma levels during cardiopulmonary bypass. Anesth Analg 1997;85:248-251.
14. Gelman S. Anesthesia and the liver. In: Barash PG, ed. Clinical Anesthesia. Philadelphia: Lippincott-Raven Publishers; 1996: 1003-1023.
15. Ramsay MAE. The use of antifibrinolytic agents results in a reduction in transfused blood products during liver transplantation. Liver Transpl 1997;3:665-668.
16. Kufner RP. Antifibrinolytics do not reduce transfusion requirements in patients undergoing orthotopic liver transplantation. Liver Transpl 1997;3:668-674.
17. McSorley MW, Taraporewalla KJ. Does prophylactic epsilon-aminocaproic acid improve blood loss and coagulation in liver transplantation? Transplant Proc 1991;23:1941.
18. Kang Y. Clinical use of synthetic antifibrinolytic agents during liver transplantation. Semin Thromb Hemost 1993;19:258-261.
19. Kiszka-Kanowitz M, Henriksen JH, Moller S, Bendsen F. Blood volume distribution in patients with cirrhosis: aspects of the dual head gamma-camera technique. J Hepatol 2001;35:605-612.
20. Baraka A, Gabali F. Correlation between tubocurarine requirements and plasma protein pattern. Br J Anaesth 1968; 40:89-93.
21. Duvaldestin P, Agoston S, Henzel D, Kerstein UW, Desmonts JM. Pancuronium pharmacokinetics in patients with liver cirrhosis. Br J Anaesth 1978;50:1131-1136.
22. Butterworth J, James RL, Lin YA, Bennett J, Prielipp RC. Gender does not influence epsilon-aminocaproic acid concentrations in adults undergoing cardiopulmonary bypass. Anesth Analg 2001;92:1384-1390.
23. Vander Salm TJ, Kant S, Lancey RA, Okike ON, Pezzella AT, Stahl RF, Leone L, Li JM, Valeri CR, Michelson AD. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 1997;112:1098-1107.
24. Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost 2001;27:657-666.